Nanoencapsulation of tacrolimus in lipid-core nanocapsules showed similar immunosuppressive activity after oral and intraperitoneal administrations.

@article{Friedrich2014NanoencapsulationOT,
  title={Nanoencapsulation of tacrolimus in lipid-core nanocapsules showed similar immunosuppressive activity after oral and intraperitoneal administrations.},
  author={Rossana B Friedrich and Frantiescoli A. Dimer and S{\'i}lvia Stanisçuaski Guterres and Ruy Carlos Ruver Beck and Adriana Raffin Pohlmann},
  journal={Journal of biomedical nanotechnology},
  year={2014},
  volume={10 8},
  pages={1599-609}
}
Tacrolimus is widely used in the prophylaxis of solid-organ transplant rejection. Several studies have reported that tacrolimus has variable and poor bioavailability after oral administration, apart from adverse effects such as gastrointestinal disorders, hyperglycemia, nephro- and neurotoxicity. The aim of this work was to encapsulate tacrolimus (TAC) in lipid-core nanocapsules (LNC) as an oral strategy to deliver the drug. To validate our hypothesis, the pharmacodynamic effect of TAC-LNC was… CONTINUE READING

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…